Cargando…

Patient-derived parathyroid organoids as a tracer and drug-screening application model

Parathyroid diseases are characterized by dysregulation of calcium homeostasis and alterations in parathyroid hormone (PTH) excretion. The development of parathyroid-targeted treatment and imaging tracers could benefit from in vitro models. Therefore, we aim to establish a patient-derived parathyroi...

Descripción completa

Detalles Bibliográficos
Autores principales: Noltes, Milou E., Sondorp, Luc H.J., Kracht, Laura, Antunes, Inês F., Wardenaar, René, Kelder, Wendy, Kemper, Annelies, Szymanski, Wiktor, Zandee, Wouter T., Jansen, Liesbeth, Brouwers, Adrienne H., Coppes, Robert P., Kruijff, Schelto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669499/
https://www.ncbi.nlm.nih.gov/pubmed/36306782
http://dx.doi.org/10.1016/j.stemcr.2022.09.015
_version_ 1784832113391960064
author Noltes, Milou E.
Sondorp, Luc H.J.
Kracht, Laura
Antunes, Inês F.
Wardenaar, René
Kelder, Wendy
Kemper, Annelies
Szymanski, Wiktor
Zandee, Wouter T.
Jansen, Liesbeth
Brouwers, Adrienne H.
Coppes, Robert P.
Kruijff, Schelto
author_facet Noltes, Milou E.
Sondorp, Luc H.J.
Kracht, Laura
Antunes, Inês F.
Wardenaar, René
Kelder, Wendy
Kemper, Annelies
Szymanski, Wiktor
Zandee, Wouter T.
Jansen, Liesbeth
Brouwers, Adrienne H.
Coppes, Robert P.
Kruijff, Schelto
author_sort Noltes, Milou E.
collection PubMed
description Parathyroid diseases are characterized by dysregulation of calcium homeostasis and alterations in parathyroid hormone (PTH) excretion. The development of parathyroid-targeted treatment and imaging tracers could benefit from in vitro models. Therefore, we aim to establish a patient-derived parathyroid organoid model representing human parathyroid tissue. Hyperplastic parathyroid tissue was dispersed, and parathyroid organoids (PTOs) were cultured and characterized. PTO-derived cells exhibited self-renewal over several passages, indicative of the presence of putative stem cells. Immunofluorescence and RNA sequencing confirmed that PTOs phenocopy hyperplastic parathyroid tissue. Exposure of PTOs to increasing calcium concentrations and PTH-lowering drugs resulted in significantly reduced PTH excretion. PTOs showed specific binding of the imaging tracers (11)C-methionine and (99m)Tc-sestamibi. These data show the functionality of PTOs resembling the parathyroid. This PTO model recapitulates the originating tissue on gene and protein expression and functionality, paving the way for future physiology studies and therapeutic target and tracer discovery.
format Online
Article
Text
id pubmed-9669499
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96694992022-11-18 Patient-derived parathyroid organoids as a tracer and drug-screening application model Noltes, Milou E. Sondorp, Luc H.J. Kracht, Laura Antunes, Inês F. Wardenaar, René Kelder, Wendy Kemper, Annelies Szymanski, Wiktor Zandee, Wouter T. Jansen, Liesbeth Brouwers, Adrienne H. Coppes, Robert P. Kruijff, Schelto Stem Cell Reports Article Parathyroid diseases are characterized by dysregulation of calcium homeostasis and alterations in parathyroid hormone (PTH) excretion. The development of parathyroid-targeted treatment and imaging tracers could benefit from in vitro models. Therefore, we aim to establish a patient-derived parathyroid organoid model representing human parathyroid tissue. Hyperplastic parathyroid tissue was dispersed, and parathyroid organoids (PTOs) were cultured and characterized. PTO-derived cells exhibited self-renewal over several passages, indicative of the presence of putative stem cells. Immunofluorescence and RNA sequencing confirmed that PTOs phenocopy hyperplastic parathyroid tissue. Exposure of PTOs to increasing calcium concentrations and PTH-lowering drugs resulted in significantly reduced PTH excretion. PTOs showed specific binding of the imaging tracers (11)C-methionine and (99m)Tc-sestamibi. These data show the functionality of PTOs resembling the parathyroid. This PTO model recapitulates the originating tissue on gene and protein expression and functionality, paving the way for future physiology studies and therapeutic target and tracer discovery. Elsevier 2022-10-27 /pmc/articles/PMC9669499/ /pubmed/36306782 http://dx.doi.org/10.1016/j.stemcr.2022.09.015 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Noltes, Milou E.
Sondorp, Luc H.J.
Kracht, Laura
Antunes, Inês F.
Wardenaar, René
Kelder, Wendy
Kemper, Annelies
Szymanski, Wiktor
Zandee, Wouter T.
Jansen, Liesbeth
Brouwers, Adrienne H.
Coppes, Robert P.
Kruijff, Schelto
Patient-derived parathyroid organoids as a tracer and drug-screening application model
title Patient-derived parathyroid organoids as a tracer and drug-screening application model
title_full Patient-derived parathyroid organoids as a tracer and drug-screening application model
title_fullStr Patient-derived parathyroid organoids as a tracer and drug-screening application model
title_full_unstemmed Patient-derived parathyroid organoids as a tracer and drug-screening application model
title_short Patient-derived parathyroid organoids as a tracer and drug-screening application model
title_sort patient-derived parathyroid organoids as a tracer and drug-screening application model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669499/
https://www.ncbi.nlm.nih.gov/pubmed/36306782
http://dx.doi.org/10.1016/j.stemcr.2022.09.015
work_keys_str_mv AT noltesmiloue patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT sondorpluchj patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT krachtlaura patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT antunesinesf patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT wardenaarrene patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT kelderwendy patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT kemperannelies patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT szymanskiwiktor patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT zandeewoutert patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT jansenliesbeth patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT brouwersadrienneh patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT coppesrobertp patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel
AT kruijffschelto patientderivedparathyroidorganoidsasatraceranddrugscreeningapplicationmodel